Success Stories: EB-1A Approved for Research Fellow in Tennessee in the Field of Biochemistry
Client’s Testimonial:
Thank you so much for your help. Your professional and high quality work is critical for my I-140 approval.
On May 12, 2015, We Received another EB1-A (Alien of Extraordinary Ability) Approval for a Research Fellow in the Field of Biochemistry (Approval Notice)
Position at the Time of Case Filing: Research Fellow
Country of Origin: China
State of Residence at the Time of Filing: Tennessee
Approval Notice Date: May 12, 2015
Processing Time: 28 Days (13 Days after Premium Processing Requested)
In this case, the client that we had the opportunity to work with was a research fellow from China in the field of biochemistry. He had conducted his research in the highly specialized area of the proteins involved in the survival and proliferation of cancer cells. His work had resulted in 9 peer-reviewed scientific articles, 1 book chapter, and 2 presentations at national and international conferences; at the time that his case was filed, his publications had been cited at least 155 times by independent and leading researchers from prestigious institutions and organizations around the world, indicating the major significance of his work. He had also reviewed 27 manuscripts for at least 9 distinctive, internationally-circulated journals. His superior level of expertise was confirmed in the following quote from a recommender, “[Client] expertly uses fragment-based drug design in my laboratory to discover drugs that target epigenetic proteins [...]. Targeted therapy is a newer cancer treatment that involves small molecule drugs that interfere with proteins that play a role in cancer cell growth and survival. Targeted cancer therapies are more efficient and less harmful to normal tissues than traditional chemotherapy drugs, which is why scientists have been so eager in recent years to develop these kinds of therapies. In our study, we first identify target proteins that are instrumental in cancer cell growth and survival in order to design small molecule drugs that target these proteins.” It was our goal to prove that our client qualified for classification as an Alien of Extraordinary Ability given that he sought to remain in the United States to continue work in the area of biochemistry, and that his continued research would substantially and prospectively benefit the United States. With the proof and documentation that we provided, his case was approved in 28 days.